Literature DB >> 6817760

The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue.

R Matzky, H Darius, K Schrör.   

Abstract

The influence of pentoxifylline (Trental) on prostacyclin (PGI2) formation was studied in vitro, using preparations of human umbilical arteries and veins. In addition, the thromboxane formation in human platelets was investigated. Pentoxifylline at 11 mumol/l concentration stimulated PGI2-release from umbilical veins from 14 +/- 8 to 28 +/- 4 pmol/100 mm2 (P less than 0.05). Similarly, pentoxifylline stimulated PGI2-formation in umbilical arteries at 36 and 110 mumol/l concentration from 12 +/- 2 to 23 +/- 10 and 25 +/- 4 pmol/100 mm2, respectively (P less than 0.05). These amounts of pentoxifylline also produced dose-dependent relaxation of venous and arterial vessel strips but did not change the ADP- or collagen-induced platelet aggregation in platelet-rich plasma in vitro. There was no influence by pentoxifylline on the arachidonic acid-induced thromboxane formation of human platelets. These data demonstrate for the first time stimulation of PGI2-formation in human blood vessels by pentoxifylline in vitro. It is suggested, that the antiplatelet effects of pentoxifylline in vivo may be mediated by primary vascular mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817760

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial.

Authors:  Namdeo Prabhu; Sanjay S Rao; S M Kotrashetti; Shridhar D Baliga; Seema R Hallikerimath; Punnya V Angadi; Rakhi Issrani
Journal:  J Maxillofac Oral Surg       Date:  2013-09-13

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells.

Authors:  S O Sowemimo-Coker; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

Review 5.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia.

Authors:  W Gallenkämper; W Rücker; K Schrör
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

7.  Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Jesús Chahin; María L Méndez; Eduardo Gallego; Manuel Macía; Nieves del Castillo; Antonio Rivero; María A Getino; Patricia García; Ana Jarque; Javier García
Journal:  J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 10.121

8.  The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse.

Authors:  P L Sensky; V E Prise; A E Ward; D G Hirst
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.